06 0 59-1 88 0 85         Surgery (complete vs non complete) 52 0

06 0.59-1.88 0.85         Surgery (complete vs non complete) 52 0.29 0.15-.058 4.97 E-07 51 0.43 0.19-0.94 0.034 Complete clinical remission (Yes vs No) 51 0.22 0.11-0.45 3.65 E-05 51 0.33 0.15-0.74 0.007 CA-125 (normal vs >normal) 44 1.87 0.84-4.16 0.12         Treatment (CCA vs HDC) 52 2.44 1.14-5.25 0.02 51 2.31 1.06-5.04 0.036 PFS, progression-free

survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; CCA, conventional chemotherapy alone; HDC, high-dose chemotherapy. We then explored the impact of chemotherapy regimen on OS according to the two factors independently associated ACP-196 cost with a PFS improvement induced by HDC (young age and FIGO stage IIIc). We could ABT-737 solubility dmso observe that HDC plus HSCS significantly improved survival only when age was under 50 years, but not in stage IIIc patients (Figure 4). Median overall survival was highly increased in young patients treated with HDC (54.6 months) when compared to conventional therapy alone (36 months), (p=0.05). Effect of HDC according to FIGO stage IIIc was less important and non significant: median OS was 53.9 months in the HDC subset versus 41.3 months in the CCA subset (p=0.11). Figure 4 Overall survival after conventional chemotherapy alone (black) or

plus high dose chemotherapy (grey). (A) In patients under 50 years of age (n=52) median OS was 36 months in the CCA subset versus 54.6 months in the HDC subset; (B) in stage IIIc cases (n=129) median OS was 42 months in the CCA subset versus 49.5 months in the HDC subset; + censored data. It is worth to note that the prognostic value of HDC was not modified by the initial response to treatment. HDC improved survival in young patients whatever the response to initial therapy was: median PFS was 5 months for CCA vs. 15 months

for HDC in patients with residual disease after treatment; and 38 months for CCA whereas it had not been reached after a follow-up of 47 months in the HDC group for cases with initial CCR and CA-125 normalization. Discussion Even though HDC plus HSCS cannot be considered as a standard of care for all AOC patients, results from this monocentric comparative FER retrospective study including 163 patients suggest that it may be beneficial to young patients. In women under 50 years of age, addition of HDC to platinum/taxane-based chemotherapy improves not only PFS (p=0.02), but also OS (median of 54.6 months versus 36 months with conventional therapy alone, p=0.05). Despite advances in chemotherapy and multidisciplinary management of ovarian carcinomas, the prognosis of patients with advanced stages (FIGO III/IV) remains poor. Median PFS and OS of our cohort treated with a platinum/taxane combination alone (18.1 and 41.3 months, respectively) were similar to those of phase III pivotal studies: 18 and 38 months [10], and 19.4 and 48.7 months [6] with cisplatin and paclitaxel; 20.7 and 57.4 months for carboplatin and paclitaxel [6].

Like all other human malignancies, prostate cancer cells escape a

Like all other human malignancies, prostate cancer cells escape apoptotic death through highly efficient pathways involving multiple mechanisms [6, 7]. X-linked inhibitor of apoptosis protein-associated factor-1 (XAF1) was first identified as an interacting protein of X-linked inhibitor of apoptosis (XIAP) [8]. XIAP suppresses apoptotic cell death by binding to caspases and inhibiting their functions. XAF1 antagonizes XIAP activities, thereby promoting apoptosis [9]. XAF1 can dramatically sensitize cancer cells to apoptotic triggers

such as TRAIL, etoposide treatments 5-fluorouracil [10], H2O2, c-irradiation, ultraviolet [11], and tumour necrosis factor-α, which are independent of its interaction with XIAP [12]. XAF1 is therefore believed to play an important role in the major apoptosis-related pathways. XAF1 also serves as a candidate tumour suppressor gene. Loss of XAF1 has been observed in a variety BIX 1294 ic50 of cancer cell

lines and human cancers [13–16]. However, little is yet known about its potential selleck inhibitor implication in prostate cancer. So far, there have been no effective therapeutic measures for the treatment of hormone refractory prostate cancer. Treatment with somatostatin may therefore be a possible therapeutic alternative to chemotherapy in hormone refractory prostate cancer patients. Somatostatin, originally identified as a neuropeptide inhibiting growth hormone release more than 30 years ago, is widely present in central and peripheral human cells/tissues including prostate. Somatostatin has been shown to exert a potent anti-tumour action by affecting tumour cell proliferation, apoptosis, angiogenesis and the host’s immune response [17–21]. Octreotide is an analogue of somatostatin and has been used in clinical practice since data emerged in the 1980 s confirming its ability to palliate carcinoid syndrome

[22]. Our previous results have shown that somatostatin may affect the mitochondria Oxaprozin of LNCaP and DU145 cells in a way that eventually triggers mitochondrial-mediated apoptosis and exert its effects on prostate cancer cells via MAPK pathway and by regulating the activities of phosphotyrosine phosphatases [23]. In the current study, we examined XAF1 mRNA and protein expression in four cell lines, and determined regulatory effects of somatostatin and Octreotide on XAF1 expression in prostate cancer cell lines. We found that somatostatin and Octreotide up-regulated XAF1 mRNA and protein expression in prostate cancer cell lines. The enhanced XAF1 expression by somatostatin indicates a promising strategy for prostate cancer therapy. Materials and methods Cell lines and cell culture A human prostate epithelial cell line (RWPE-1) and prostate cancer cell lines (LNCaP, DU145 and PC3) were used and were obtained from the American Type Culture Collection (ATCC). LNCaP, DU145 and PC3 were maintained in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS).

GLPG0259 free base is poorly soluble in aqueous media, and its so

GLPG0259 free base is poorly soluble in aqueous media, and its solubility decreases with increasing pH (<0.01 mg/mL at pH 7). Two approaches were developed in parallel to overcome this low solubility and to improve compound bioavailability after dosing in a solid dosage form. The first approach was a salt screening, AZD5363 which resulted in the selection of the fumarate salt for further formulation development work. The water solubility of

the GLPG0259 fumarate salt, as compared with that of the free base, was increased to 1.9–2.7 mg/mL. The impact of the improvement in solubility was confirmed in a comparative bioavailability study in fasted dogs. In that study, GLPG0259 fumarate salt (suspension in 20% [w/v] hydroxypropyl-ß–cyclodextrin, pH 3, or as crystalline powder in capsule form) resulted in plasma exposure similar to that of GLPG0259 free base in suspension in 20% acidified hydroxypropyl-ß–cyclodextrin, but 4-fold higher plasma exposure than that of GLPG0259 free-base crystalline powder in capsule form (data not shown). In humans, administration of GLPG0259 fumarate salt as a crystalline powder in capsule form leads to 50% lower bioavailability than that of GLPG0259 free base

given as a solution in 40% (w/v) hydroxypropyl-ß–cyclodextrin, pH 3 (study 3). The lower performance of the fumarate capsule in humans than in dogs is explained by the higher percentage of hydroxypropyl-ß–cyclodextrin (40% versus 20%) in the liquid formulation, which enhances GLPG0259 free-base solubility. Bafilomycin A1 mouse Concomitant food intake with the solid

dosage form Sitaxentan prevents this decrease in bioavailability by increasing the solubility further. The second approach was the improvement of GLPG0259 solubility by physical modifications of the drug substance – in particular, the development of solid dispersion formulations with GLPG0259 free base in an amorphous form homogenously dispersed in a polymer matrix. The free-base solid dispersion as a powder or pellets filled into capsules was tested in fasted dogs, and both solid dispersion formulations showed GLPG0259 plasma exposure similar to that of the fumarate salt as a crystalline powder in capsule form. Similar results were obtained in humans (study 4). In the Biopharmaceutical Classification System, drugs are classified according to measurements of solubility and permeability.[20] Regarding GLPG0259, it is a poorly soluble compound, with solubility that decreases with increased pH. The absorption of GLPG0259 was not measured in vivo in humans (there are no data after intravenous dosing), but its permeability assessed using the well established in vitro system, based on the human adenocarcinoma cell line Caco-2, was good, with an apparent permeability coefficient (Papp) of 12.4 10-6 cm/s and limited efflux (Papp B2A/Papp A2B = 2).

Curr Opin Infect Dis 16:129–134PubMedCrossRef Murphy TF, Brauer A

Curr Opin Infect Dis 16:129–134PubMedCrossRef Murphy TF, Brauer AL, Sethi S, Kilian M, Cai X, U0126 supplier Lesse AJ (2007) Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis 195:81–89PubMedCrossRef Musk DJ, Hergenrother PJ (2006) Chemical countermeasures for the control of bacterial biofilms: effective compounds and promising targets. Curr Med Chem 13:2163–2177PubMedCrossRef National Committee for Clinical Laboratory Standards (2000) Approved standard: M2-A7. Performance standards for antimicrobial disk susceptibility tests, 7th ed. National Committee

for Clinical Laboratory Standards, Wayne, Pennsylvania 19087-1898, USA National Committee

for Clinical Laboratory Standards (2004) Quality control for commercially prepared microbiological culture media; approved standard—third edition. NCCLS document M22-A3. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA Oancea S (2010) An overview of conventional and alternative strategies for developing new antibacterial agents. Acta Chim Slov 57:630–642PubMed Pillai A, Mitchell selleck inhibitor JL, Hill SL, Stockley RA (2000) A case of Haemophilus parainfluenzae pneumonia. Thorax 55:623–624PubMedCrossRef Pitucha M, Mazur L, Kosikowska U, Pachuta-Stec A, Malm A, Popiołek Ł, Rzączyńska Z (2010) Synthesis, structure and antibacterial evaluation of new N-substituted-3-amino-5-oxo-4-phenyl-2,5-dihydro-1H-pyrazole-1-carbothioamides. Heteroat Chem 21:215–221 Prakash Clostridium perfringens alpha toxin B, Veeregowda BM, Krishnappa G (2003) Biofilms: a survival strategy of bacteria. Curr Sci India 85:1299–1307 Raffa RB, Iannuzzo

JR, Levine DR, Saeid KK, Schwartz RC, Sucic NT, Terleckyj OD, Young JM (2005) Bacterial communication (quorum sensing) via ligands and receptors: a novel pharmacologic target for the design of antibiotic drugs. J Pharmacol Exp Ther 312:417–423PubMedCrossRef Raoult D, Drancourt M, Gallais H, Casanova P (1987) Haemophilus parainfluenzae meningitis in an adult with an inherited deficiency of the seventh component of complement. Arch Intern Med 417:2214CrossRef Reece RJ, Maxwell A (1991) DNA gyrase: structure and function. Crit Rev Biochem Mol 26:335–375CrossRef Rele M, Giles M, Daley AJ (2006) Invasive Haemophilus parainfluenzae maternal-infant infections: an Australasian perspective and case report. Aust N Z J Obstet Gynaecol 46:258–260PubMedCrossRef Rennie R, Gordon T, Yaschuk Y, Tomlin P, Kibsey P, Albritton W (1992) Laboratory and clinical evaluations of media for the primary isolation of Haemophilus species. J Clin Microbiol 30:1917–1921PubMedCentralPubMed Sanclement JA, Webster P, Thomas J, Ramadan HH (2005) Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis.